For example, a potential trial could be topical application of the TRPV4 selective inhibitor for treating chronic itch, based on recent exciting findings about keratinocyte TRPV4 in cholestatic itch [16] and dry-skin-associated itch [19]. This evidence concerns the gene TRPV4 and Dry skin.